These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 21394020

  • 1. Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.
    Ravaud A, Bello CL.
    Anticancer Drugs; 2011 Jun; 22(5):377-83. PubMed ID: 21394020
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib for the management of advanced renal cell carcinoma.
    Escudier B.
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
    [Abstract] [Full Text] [Related]

  • 3. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL.
    J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
    [Abstract] [Full Text] [Related]

  • 4. Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.
    Castellano D, Ravaud A, Schmidinger M, De Velasco G, Vazquez F.
    Cancer Treat Rev; 2013 May; 39(3):230-40. PubMed ID: 22647546
    [Abstract] [Full Text] [Related]

  • 5. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
    Shi HZ, Tian J, Chen X, Wang D, Li CL.
    Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
    Kim JH, Park I, Lee JL.
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.
    Chemotherapy; 2012 Aug; 58(6):468-74. PubMed ID: 23548259
    [Abstract] [Full Text] [Related]

  • 15. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
    Kruse V, Somers A, Van Bortel L, De Both A, Van Belle S, Rottey S.
    J Clin Pharm Ther; 2014 Jun; 39(3):259-65. PubMed ID: 24417304
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
    Schmidinger M, Arnold D, Szczylik C, Wagstaff J, Ravaud A.
    Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.